Literature DB >> 31768799

Upfront Therapies and Downstream Effects: Navigating Late Effects in Childhood Cancer Survivors in the Current Era.

Rachel Phelan1, Hesham Eissa2, Kerri Becktell3, Neel Bhatt4, Matthew Kudek3, Brandon Nuechterlein2, Lauren Pommert3, Ryuma Tanaka3, K Scott Baker4.   

Abstract

PURPOSE OF REVIEW: As survival rates of those diagnosed with childhood cancer improve over time, the number of long-term survivors continues to grow. Advances have not only been made in the upfront treatment of childhood cancer, but also in the identification and treatment of late complications that may arise as a result of the chemotherapy, radiotherapy, or surgical interventions required to provide a cure. RECENT
FINDINGS: As new therapies emerge that are often more targeted to cancerous cells while sparing healthy tissues, the hope is that cure can be achieved without the same long-term side effects for survivors. However, much is unknown regarding how these novel interventions will impact patients in the years to come. It is critical that we continue to follow patients treated with new modalities in order to identify and treat the long-term complications that may arise in future childhood cancer survivors.

Entities:  

Keywords:  Childhood cancer; Late effects; Long-term complications; Novel therapy; Survivorship

Mesh:

Year:  2019        PMID: 31768799     DOI: 10.1007/s11912-019-0861-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  87 in total

1.  Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study.

Authors:  Smita Bhatia; Liton Francisco; Andrea Carter; Can-Lan Sun; K Scott Baker; James G Gurney; Philip B McGlave; Auayporn Nademanee; Margaret O'Donnell; Norma K C Ramsay; Leslie L Robison; David Snyder; Anthony Stein; Stephen J Forman; Daniel J Weisdorf
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

2.  Second malignancies in patients with neuroblastoma: the effects of risk-based therapy.

Authors:  Mark A Applebaum; Tara O Henderson; Sang Mee Lee; Navin Pinto; Samuel L Volchenboum; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2014-09-23       Impact factor: 3.167

3.  Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants.

Authors:  Amy E Armstrong; Karina Danner-Koptik; Shannon Golden; Jennifer Schneiderman; Morris Kletzel; Jennifer Reichek; Yasmin Gosiengfiao
Journal:  J Pediatr Hematol Oncol       Date:  2018-01       Impact factor: 1.289

4.  Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS).

Authors:  Saro H Armenian; Can-Lan Sun; Toana Kawashima; Mukta Arora; Wendy Leisenring; Charles A Sklar; K Scott Baker; Liton Francisco; Jennifer Berano Teh; George Mills; F Lennie Wong; Joseph Rosenthal; Lisa R Diller; Melissa M Hudson; Kevin C Oeffinger; Stephen J Forman; Leslie L Robison; Smita Bhatia
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

5.  Survival and late effects in children with stage 4 neuroblastoma.

Authors:  Thomas Perwein; Herwig Lackner; Petra Sovinz; Martin Benesch; Sandrin Schmidt; Wolfgang Schwinger; Christian Urban
Journal:  Pediatr Blood Cancer       Date:  2011-02-11       Impact factor: 3.167

6.  Late effects of radiotherapy for pediatric extremity sarcomas.

Authors:  Arnold C Paulino
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-09-01       Impact factor: 7.038

Review 7.  Thrombosis in children with malignancy.

Authors:  Laszlo Bajzar; Anthony K Chan; Mary Patricia Massicotte; Lesley G Mitchell
Journal:  Curr Opin Pediatr       Date:  2006-02       Impact factor: 2.856

8.  A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.

Authors:  Anuradha Banerjee; Regina I Jakacki; Arzu Onar-Thomas; Shengjie Wu; Theodore Nicolaides; Tina Young Poussaint; Jason Fangusaro; Joanna Phillips; Arie Perry; David Turner; Michael Prados; Roger J Packer; Ibrahim Qaddoumi; Sridharan Gururangan; Ian F Pollack; Stewart Goldman; Lawrence A Doyle; Clinton F Stewart; James M Boyett; Larry E Kun; Maryam Fouladi
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300

9.  The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE).

Authors:  Nickhill Bhakta; Qi Liu; Kirsten K Ness; Malek Baassiri; Hesham Eissa; Frederick Yeo; Wassim Chemaitilly; Matthew J Ehrhardt; Johnnie Bass; Michael W Bishop; Kyla Shelton; Lu Lu; Sujuan Huang; Zhenghong Li; Eric Caron; Jennifer Lanctot; Carrie Howell; Timothy Folse; Vijaya Joshi; Daniel M Green; Daniel A Mulrooney; Gregory T Armstrong; Kevin R Krull; Tara M Brinkman; Raja B Khan; Deo K Srivastava; Melissa M Hudson; Yutaka Yasui; Leslie L Robison
Journal:  Lancet       Date:  2017-09-08       Impact factor: 79.321

Review 10.  Late Effects and Survivorship Issues in Patients with Neuroblastoma.

Authors:  Danielle Novetsky Friedman; Tara O Henderson
Journal:  Children (Basel)       Date:  2018-08-06
View more
  2 in total

1.  Unconventional Oil and Gas Development Exposure and Risk of Childhood Acute Lymphoblastic Leukemia: A Case-Control Study in Pennsylvania, 2009-2017.

Authors:  Cassandra J Clark; Nicholaus P Johnson; Mario Soriano; Joshua L Warren; Keli M Sorrentino; Nina S Kadan-Lottick; James E Saiers; Xiaomei Ma; Nicole C Deziel
Journal:  Environ Health Perspect       Date:  2022-08-17       Impact factor: 11.035

2.  Childhood survivors of high-risk neuroblastoma show signs of immune recovery and not immunosenescence.

Authors:  Petra Lázničková; Tomáš Kepák; Marcela Hortová-Kohoutková; Luděk Horváth; Kateřina Sheardová; Rafal Marciniak; Carmine Vacca; Michaela Šiklová; Teresa Zelante; Lenka Rossmeislová; Zdenka Křenová; Jaroslav Štěrba; Kamila Bendíčková; Jan Frič
Journal:  Eur J Immunol       Date:  2020-08-18       Impact factor: 5.532

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.